The CC genotype of the GNAS T393C polymorphism is associated with obesity and insulin resistance in women with polycystic ovary syndrome

Susanne Hahn, Ulrich H Frey¹, Winfried Siffert¹, Susanne Tan², Klaus Mann² and Onno E Janssen²

Endokrinologikum Ruhr, Center for endocrine and metabolic diseases, Alter Markt 4, 44866 Bochum, Germany, ¹Institute of Pharmacogenetics, and ²Division of Endocrinology, Department of Medicine, University Hospital of Essen Medical School, Essen, Germany

(Correspondence should be addressed to S Hahn; Email: susanne.hahn@endokrinologikum.com)

Abstract

Objective: Variants in the Gs protein α subunit gene (GNAS1) are known to be involved in the pathogenesis of several endocrine and metabolic disorders. To understand genetic determinants of androgen excess, insulin resistance, and obesity in polycystic ovary syndrome (PCOS), we investigated the effect of the common GNAS1 T393C polymorphism on the phenotype of German PCOS women.

Design: Two hundred and seventy-eight PCOS women and 820 Caucasian controls were genotyped for the common T393C polymorphism in GNAS1. To this end, genomic DNA was amplified by PCR with specific oligonucleotides and genotypes were determined using the restriction enzyme FokI. In addition, we evaluated whether the T393C polymorphism had an influence on the response to 6 months metformin treatment in a subgroup of 105 PCOS women.

Methods: Anthropometric variables, metabolic parameters including indices of insulin resistance measured by oral glucose tolerance testing, and endocrine biochemical as well as clinical parameters were measured in all PCOS subjects.

Results: GNAS1 genotype distributions were not significantly different between PCOS women and controls. In PCOS women, no significant differences in endocrine clinical and biochemical variables were found between the genotypes. However, the C-allele carrier group had significantly higher mean body weight, body mass index, leptin levels, and higher indices of insulin resistance compared with women with GNAS1 TT-genotype. Metformin treatment significantly improved hyperandrogenism, menstrual cyclicity, body weight, and insulin resistance independent of GNAS1 genotype. The major determinant of weight loss was body weight before treatment.

Conclusion: The T393C polymorphism is not associated with PCOS in Caucasian women, but may represent a genetic marker for increased susceptibility for obesity in this cohort.
A possible approach to identify susceptibility genes for obesity or PCOS per se is to test the association between clinical characteristics and a specific allele of a gene that appears to be a good candidate gene, for example, a gene involved in hormone production and insulin metabolism, like the gene GNAS1 encoding for the Gs protein α subunit (Gas), which is located at 20q13.2–13.3, a locus that has previously been linked to obesity (18). Gas, which couples receptor binding by several hormones to activation of adenylate cyclase, is one member of a large family of G-proteins that are integral components of diverse signaling pathways (19). In mice, the arrest of meiotic prophase oocytes within antral follicles requires the G-protein G(s) and the orphan Gs-linked receptor GPR3 (20–22). In humans, several endocrine disorders are associated with somatic GNAS1 mutations (23, 24). In young girls with premature thelarche, the R201H-activating mutation in the GNAS1 was suggested to cause ovarian hyperfunction (25). In addition, the Gas protein system has been shown to play an important role in the metabolic and the cardiovascular system. In animal models, mice with heterozygous disruption of the GNAS paternal allele are lean, hypermetabolic, and present with an increased whole body insulin sensitivity (26). In humans, heterozygous Gas null mutations lead to Albright hereditary osteodystrophy, a syndrome, among other symptoms, characterized by obesity (27). Genetic variation of G-proteins may play an important role not only in complex diseases, but also in drug responses. Jia et al. hypothesized that the GNAS1 locus carries a functional variant influencing the response to β-blockade in hypertensive patients (28). Interactions between genes and therapeutic interventions were also found for several other genes. In PCOS women, Ertunc et al. found a differential effect of metformin therapy on the basis of IRS genotypes (29).

To understand genetic determinants of androgen excess, insulin resistance, and obesity in PCOS women, we investigated the effect of the common GNAS1 T393C polymorphism on the phenotype of German PCOS women. In addition, we evaluated whether genotypes of the T393C polymorphism had an influence on the response to metformin treatment.

**Subjects and methods**

**Subject recruitment**

**PCOS patients** From the outpatient clinics of the Division of Endocrinology, Department of Medicine and the Department of Obstetrics and Gynecology at the University Hospital of Essen Medical School, 278 PCOS patients seeking medical advice for cycle abnormalities, hirsutism, obesity, or infertility were prospectively and consecutively recruited. Based on the criteria derived from the 1990 NIH conference, diagnosis of PCOS was established when either oligomenorrhea (cycles lasting longer than 35 days) or amenorrhea (less than two menstrual cycles in the past 6 months) and either clinical signs of hyperandrogenism (hirsutism or obvious acne or alopecia and/or an elevated total testosterone in combination with an elevated free androgen index (FAI) (normal range: testosterone < 2.0 nmol/L, FAI < 3.8) were found, and other pituitary, adrenal, or ovarian diseases could be excluded. Therefore, laboratory analysis of luteinizing hormone (LH), follicle-stimulating hormone (FSH), estradiol, prolactin, cortisol, adrenocorticotropic hormone (ACTH), thyroid-stimulating hormone (TSH), insulin-like growth factor (IGF)-1, androstendione, and DHEA sulfate was performed in each woman. In addition, in all women an ACTH test with measurement of 17-hydroxyprogesterone was performed. When the stimulated value was > 10 ng/ml, a genetic analysis (21 hydroxylase deficiency) was added. Hirsutism was routinely graded by two physicians independently using the common modified Ferriman–Gallwey score (FG). FG scores never differed by more than 2 and when not identical were re-evaluated by a third physician and the median value used. Hirsutism was diagnosed when a score above 5 was evaluated. All PCOS women also fulfilled the 2003 - Rotterdam criteria (30). PCOS women were not taking any medication known to affect carbohydrate and lipid metabolism or endocrine parameters for at least 3 months before entering the study. All PCOS women were of Caucasian origin. The study protocol was approved by the Ethics Committee of the University of Essen. Written informed consent was obtained from all participants.

**Control population** The Caucasian control sample consisted of 820 healthy white blood donors, who were recruited at the local Department for Transfusion Medicine, University Hospital of Essen. These individuals attend the blood bank usually every 3 months for blood donation and are under close health surveillance to guarantee high-quality blood products. According to German law, blood donors must be free of any medication and acute or chronic infectious diseases, to mention only few requirements. Thus, these individuals represent a cross-sectional sample of a young healthy German population. Among these 820 controls, healthy white women were matched for race and age with PCOS women. The 209 female age-matched blood donors had a mean age of 29.4 ± 6.2 years.

**Study protocol**

A subgroup of 124 PCOS women not wishing to take oral contraceptives received monotherapy with metformin. This sample was comparable with regard to the
clinical, endocrine, and metabolic characteristics to a larger sample of German PCOS patients, which we have recently described in detail (10). Women with body mass index (BMI) < 30 kg/m² were treated with 850 mg bid and those with BMI ≥ 30 kg/m², with 1000 mg bid. The study protocol was approved by the Ethics Committee of the University of Duisburg-Essen. All participants gave informed written consent before entering the study. In addition, a patient’s insurance was contracted for all study participants treated with metformin.

PCOS women were told not to change their lifestyle behavior (nutrition, sport) during the study period in order to make sure that a possible weight loss is only induced by metformin therapy. Patients and physicians were unaware of patients’ genotypes at any time of the study period. Out of the 124 patients, 15 PCOS women conceived during the study and were excluded from further analysis. Three women discontinued treatment because of side effects (diarrhea) and one was excluded from the analysis because she wished to take an oral contraceptive pill. Therefore, data of 105 women were available for statistical analysis.

**Clinical and laboratory parameters**

In PCOS subjects, physical examination was performed, including evaluation of hirsutism by the FG-score, the presence of acne or alopecia, and anthropometric measurements including body weight in kilograms and waist circumference in centimeters before entering the study (n=278) and in those participating in the treatment subgroup (n=105) again after 1 and 6 months on metformin. Body mass index (BMI) was calculated as weight/(height)² (kg/m²). Sitting blood pressure was measured twice after a 15-min rest from the right arm using a standard sphygmomanometer, while the appearance of the first sound (Korotkoff sound, phase I) was used to define systolic blood pressure and the disappearance of sound (phase V) defined diastolic blood pressure. We used the average of the two measurements for statistical analysis. In addition, medical history was obtained by personal interview. PCOS women were instructed to document the frequency and length of menstrual bleedings. After an overnight fast of 12 h, a 75 g-oral glucose tolerance test (OGTT) with determination of glucose and insulin levels at baseline and at 30, 60, 90, 120, and 180 min was performed. Insulin resistance was defined by the HOMA-model (31) and insulin sensitivity by evaluating the quantitative insulin-sensitivity check index (QUICKI) (32) and the Bennett index (33). In addition, whole-body insulin sensitivity (ISL_Matsuda) (34), which combines hepatic and peripheral insulin sensitivity, was calculated by the formula: 10 000/square root of [(fasting glucose × fasting insulin) × (mean glucose × mean insulin during OGTT (times 0, 30, 60, 90, and 120 min)]. Hyperinsulinemia was determined by calculating the area under the insulin response curve (AUC-I) and β-cell function by HOMA-β (31). Prior to the OGTT (between 0800 and 0900 h), blood samples were drawn for the measurement of all other metabolic and endocrine parameters. Except for amenorrhoic women, all laboratory determinations were performed in the early follicular phase of the cycle. The presence of polycystic ovaries (PCO) was defined by the ESHRE/ASRM-criteria when at least one ovary > 10 ml or with at least 12 follicles of 2–9 mm diameter was found on transvaginal ultrasound. FAI was estimated as testosterone (nmol/l)/sex hormone-binding globulin (SHBG; nmol/l) × 100.

Automated chemiluminescence immunoassay systems were used for the determination of testosterone, LH, FSH, estradiol, prolactin, cortisol, TSH, total cholesterol, HDL cholesterol, LDL cholesterol (LDL), triglycerides, and blood glucose (ADVIA Centaur, Bayer Vital, Fernwald, Germany), androstenedione, DHEA sulfate (DHEAS), SHBG, and insulin (IMMULITE 2000, DPC Biermann, Bad Nauheim, Germany). Leptin was measured using the enzymatically amplified ‘two-step’ sandwich-type ACTIVE Human Leptin ELISA kit (Diagnostic Systems Laboratories, Webster, TX, USA). Biologically active ghrelin was determined by RIA kits (LINCO Research, Inc., St. Charles, MO, USA). Intra- and interassay variations were < 5 and < 8% respectively for all measured parameters.

**DNA genotyping**

For the molecular analysis of the GNAS1 alleles, genomic DNA was isolated from whole blood with the QIAamp DNA blood kit (Qiagen, Hilden, Germany). Genotypes for the GNAS1 T393C polymorphism were determined by PCR with the forward primer 5’-CTCTAACTGACATGTTGC-3’ and the reverse primer 5’-TAAGGCCACA-CAAGTCGGGGT-3’. After denaturation at 94 °C, 35 cycles of DNA amplification were performed using Eppendorf Taq PCR Mastermix at 94 °C for 45 s, 58 °C for 40 s, and 72 °C for 45 s. The 345 bp PCR products were digested using the restriction enzyme FokI and analyzed on a 2% agarose gel. The unrestricted products (345 bp) represent the TT genotype; the completely restricted products (259 and 86 bp) represent the CC genotype.

**Statistical analysis**

Data are presented as mean±S.D. or as number and percent affected. Wherever continuous variables were compared at baseline, linear ANOVA was applied. For not normally distributed variables, Wilcoxon rank sum test (in case of two groups) or Kruskal–Wallis test (in case of more than two groups) was performed.

The Tukey honestly significant difference (HSD) post hoc test was used to determine the significant differences between group means in an ANOVA setting. Tukey’s HSD test is one of the several methods of ensuring that
the chance of finding a significant difference in any comparison (under a null model) is maintained at the $\alpha$ level of the test and therefore preserves ‘family-wise type I error’. Since the T393C polymorphism shows a gene-dose effect (35), ANOVA was used for comparison of continuous variables where appropriate. For categorical variables at baseline, the $\chi^2$ test was used; for dichotomous clinical parameters before and after metformin treatment, McNemar test for frequency distributions was calculated. To address treatment response with respect to baseline, comparisons were carried out using Wilcoxon sign rank tests or the mixed model ANOVA for repeated measures where appropriate. Differences were regarded significant at a $P$ value $<0.05$. All statistical analyses were done using SPSS version 11.0 (SPSS, Chicago, IL, USA). Box-plot graphs were computed using GraphPad Software, Inc., San Diego, CA, USA. All data are presented in SI units. Our study had more than 80% (0.82 802) statistical power to detect an OR of 1.5 with the type I error rate $\alpha=0.05$.

**Results PCOS characteristics**

Complete baseline data sets were available for a total of 278 PCOS women. The majority of these women were oligomenorrhoic (196 out of 278, 71%), the rest was amenorrhoic. Regarding clinical signs of hyperandrogenism, 36% of PCOS subjects presented with acne, 29% with mild alopecia (Ludwig score <2) and 67% with hirsutism. Mean FG hirsutism score was 9.7 $\pm$ 6.7. Elevated total testosterone levels and FAI were found in 83.1% (mean testosterone, 2.6 $\pm$ 0.9 nmol/l; mean FAI, 8.8 $\pm$ 6.9) of PCOS patients. PCO, defined by the ESHRE/ASRM-criteria, were diagnosed in 208 women (75%). Insulin resistance (HOMA-IR $>2.5$) was diagnosed in 187 out of 278 women (67.3%) (mean, 3.9 $\pm$ 3.6). Of the entire PCOS cohort, 87 (31.3%) women had normal weight (BMI $<25$ kg/m$^2$), 55 (19.8%) overweight (BMI $=25.0$–$29.9$ kg/m$^2$), and 136 (48.9%) obese (BMI $\geq30.0$ kg/m$^2$).

**Genotype distribution**

In PCOS women, GNAS1 genotypes did not differ from those evaluated in a control population of 820 randomly selected blood donors (women and men) or from an age-matched group of healthy Caucasian women (Table 1). Genotype distributions of both PCOS patients and controls were in Hardy–Weinberg equilibrium.

**Patient characteristics by GNAS1 genotype**

In PCOS women, no significant differences in endocrine variables were found between the T393C GNAS1 genotypes (Table 2). However, statistical analysis by linear ANOVA revealed that PCOS CC genotypes had significantly higher mean body weight, BMI, leptin levels, and higher indices of insulin resistance compared with women possessing GNAS1 TC or TT genotype (Table 3). Differences in body weight, BMI, and leptin levels between the CC and TT genotypes remained significant even after correcting by Tukey’s testing. Comparison of the homozygous CC and TT groups of PCOS women also found significant differences in waist circumference, $\beta$-cell function measured by HOMA-\(\beta\) and for the Matsuda index as a parameter of combined hepatic and peripheral insulin sensitivity. Significant differences in the genotype distribution according to BMI values were found ($P=0.01$). The 393C allele frequency was found to be 73.6% in normal weight women, 69.1% in overweight women, 60.9% in women with a BMI = 30.0–34.9 kg/m$^2$, 85.7% in women with a BMI $=35.0$–39.9 kg/m$^2$, and 89.6% in women with a BMI $\geq40$ kg/m$^2$. Lipid and glucose metabolism were not influenced by the T393C GNAS1 polymorphism. Mean blood pressure (CC, 125.3 $\pm$ 16.2 mmHg; TC, 125.3 $\pm$ 14.4 mmHg; TT, 124.6 $\pm$ 14.9 mmHg) and smoking status (CC, 33% smokers; TC, 30% smokers; and TT, 44% smokers) did not differ significantly between the groups. Interestingly, the percentage of PCOS women, who were physically active (sport activities at least once in a week for more than 30 min) did not differ significantly between the subgroups (CC, 54.8%; TC, 52.9%; TT, 59.4%).

Control characteristics by GNAS1 genotype. In the age-matched control group of Caucasian women ($n=209$), no significant differences in the genotype distribution according to body weight (CC, 73.3 $\pm13.3$; TC, 73.6 $\pm11.1$; TT, 75.7 $\pm11.5$ kg), BMI (CC, 26.2 $\pm4.5$; TC, 25.3 $\pm3.4$; TT, 26.4 $\pm3.7$ kg/m$^2$), or waist circumference (CC, 81.1 $\pm12.5$; TC, 78.6 $\pm12.8$; TT, 80.4 $\pm12.2$ cm) were found.

**Metformin treatment**

Patients and physicians were unaware of patients’ genotypes at any time of the study period. The genotype distribution of the 105 women treated with metformin was not statistically different from that of the entire PCOS cohort (CC, $n=28$ (26.7%); TC, $n=51$ (48.6%); TT, $n=26$ (24.8%)). Metformin therapy significantly improved FAI (Fig. 1) as a parameter of biologically active testosterone as well as total testosterone levels (CC, 2.8 $\pm1.0$–1.9 $\pm0.8$ nmol/l; TC, 2.7 $\pm1.0$–1.9 $\pm0.7$ nmol/l;

**Table 1** GNAS1 genotype distribution in polycystic ovary syndrome (PCOS) women and controls. Data are presented as number and (percentage).

<table>
<thead>
<tr>
<th></th>
<th>CC</th>
<th>TC</th>
<th>TT</th>
<th>n</th>
</tr>
</thead>
<tbody>
<tr>
<td>PCOS</td>
<td>73 (26.3%)</td>
<td>136 (48.9%)</td>
<td>69 (24.8%)</td>
<td>278</td>
</tr>
<tr>
<td>Controls (women and men)</td>
<td>235 (28.7%)</td>
<td>403 (49.1%)</td>
<td>182 (22.2%)</td>
<td>820</td>
</tr>
<tr>
<td>Age matched control women</td>
<td>57 (27.3%)</td>
<td>95 (45.4%)</td>
<td>57 (27.3%)</td>
<td>209</td>
</tr>
</tbody>
</table>
Table 2 Endocrine characteristics of PCOS women by GNAS1 genotype. Values are presented as mean and s.d. or number and percentage of affected.

<table>
<thead>
<tr>
<th></th>
<th>CC (n=73)</th>
<th>TC (n=136)</th>
<th>TT (n=69)</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>Testosterone (nmol/l)</td>
<td>2.6±0.9</td>
<td>2.6±0.9</td>
<td>2.6±0.8</td>
<td>NS</td>
</tr>
<tr>
<td>FAI</td>
<td>8.4±5.7</td>
<td>8.9±7.2</td>
<td>8.4±6.4</td>
<td>NS</td>
</tr>
<tr>
<td>Androstenedione (nmol/l)</td>
<td>3.7±1.6</td>
<td>4.1±1.8</td>
<td>4.3±1.8</td>
<td>NS</td>
</tr>
<tr>
<td>Estradiol (pmol/l)</td>
<td>225.8±170.7</td>
<td>243.2±168.5</td>
<td>222.2±139.8</td>
<td>NS</td>
</tr>
<tr>
<td>LH (U/l)</td>
<td>9.2±5.4</td>
<td>11.1±7.6</td>
<td>11.3±8.4</td>
<td>NS</td>
</tr>
<tr>
<td>FSH (U/l)</td>
<td>4.3±1.6</td>
<td>4.9±2.0</td>
<td>4.7±1.7</td>
<td>NS</td>
</tr>
<tr>
<td>DHEAS (µmol/l)</td>
<td>0.52±0.27</td>
<td>0.56±0.28</td>
<td>0.56±0.32</td>
<td>NS</td>
</tr>
<tr>
<td>Hirsutism score</td>
<td>8.9±6.4</td>
<td>9.6±6.5</td>
<td>10.6±7.4</td>
<td>NS</td>
</tr>
<tr>
<td>Amenorrhea</td>
<td>23 (32%)</td>
<td>38 (28%)</td>
<td>21 (30%)</td>
<td>NS</td>
</tr>
<tr>
<td>Oligomenorrhea</td>
<td>50 (68%)</td>
<td>98 (72%)</td>
<td>48 (70%)</td>
<td>NS</td>
</tr>
<tr>
<td>Acne</td>
<td>26 (36%)</td>
<td>54 (40%)</td>
<td>21 (30%)</td>
<td>NS</td>
</tr>
<tr>
<td>POCO</td>
<td>54 (74%)</td>
<td>103 (76%)</td>
<td>51 (74%)</td>
<td>NS</td>
</tr>
</tbody>
</table>

FAI, free androgen index; LH, luteinizing hormone; FSH, follicle-stimulating hormone; PCO, polycystic ovaries; NS, not significant.

TT, 2.9±0.9–1.9±0.7 nmol/l) in PCOS women, independent of GNAS1 genotype. Interestingly, a trend to greater changes in mean FAI levels was found in TT patients compared with C-allele carriers after 6 months on metformin (TT, ΔFAI=−4.06±5.1; TC, ΔFAI=−2.33±4.8; CC, ΔFAI=−1.83±5.2). The improvement of hyperandrogenism remained significant when the subgroup of lean PCOS women was analyzed (CC, testosterone 2.4±1.0–1.8±0.9 nmol/l, P=0.038; TC, testosterone 3.1±0.0–2.0±0.7 nmol/l, P=0.0037; TT, testosterone 2.9±1.0–1.6±0.5, P=0.044). Acne improved significantly in all PCOS women (number of affected women: CC, 12 before and 4 after treatment; TC, 10 before and 3 after treatment; TT, 21 before and 8 after treatment). Hirsutism and alopecia did not improve significantly within 6 months of treatment (data not shown). Menstrual cyclicity improved in more than half of the PCOS women studied, independent of the T393C GNAS1 polymorphism (Fig. 2). Furthermore, HOMA-IR (Fig. 3) and indices of insulin sensitivity (data not shown) improved significantly independent of GNAS1 genotype. In addition, mean body weight decreased significantly during treatment in all genotype groups (Fig. 4). Multivariate analysis confirmed that weight reduction was independent of genotype and age but depended on the body weight at baseline. When the 5% weight loss after 6 months was analyzed in the entire cohort, significant differences were found between CC and TT genotypes (P<0.05) by χ² testing, but failed to reach the level of statistical significance when an analysis

Table 3 Metabolic characteristics of PCOS women by GNAS1 genotype. Values are presented as mean ± s.d.

<table>
<thead>
<tr>
<th></th>
<th>CC (n=73)</th>
<th>TC (n=136)</th>
<th>TT (n=69)</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years)</td>
<td>27.9±6.5</td>
<td>27.6±5.9</td>
<td>27.8±5.8</td>
<td>NS</td>
</tr>
<tr>
<td>Body weight (kg)</td>
<td>90.1±27.8</td>
<td>87.4±26.8</td>
<td>80.5±19.2</td>
<td>0.026*</td>
</tr>
<tr>
<td>BMI (kg/m²)</td>
<td>31.6±9.2</td>
<td>31.0±8.9</td>
<td>28.7±6.9</td>
<td>0.044†</td>
</tr>
<tr>
<td>Waist circumference (cm)</td>
<td>95.3±20.9</td>
<td>94.3±20.7</td>
<td>89.0±14.9</td>
<td>NS²</td>
</tr>
<tr>
<td>HOMA-IR</td>
<td>4.5±4.1</td>
<td>4.0±3.8</td>
<td>3.1±2.3</td>
<td>0.023</td>
</tr>
<tr>
<td>QUICKI</td>
<td>0.327±0.037</td>
<td>0.332±0.041</td>
<td>0.341±0.042</td>
<td>NS</td>
</tr>
<tr>
<td>Bennett index</td>
<td>0.1406±0.0153</td>
<td>0.1439±0.0173</td>
<td>0.1492±0.0183</td>
<td>NS³</td>
</tr>
<tr>
<td>Matsuda index</td>
<td>3.9±3.1</td>
<td>4.9±4.1</td>
<td>5.5±4.9</td>
<td>NS⁴</td>
</tr>
<tr>
<td>Fasting insulin (pmol/l)</td>
<td>107.6±104.5</td>
<td>99.7±95.3</td>
<td>75.3±51.1</td>
<td>0.040</td>
</tr>
<tr>
<td>AUC insulin</td>
<td>306.9±213.8</td>
<td>317.2±301.7</td>
<td>273.1±206.5</td>
<td>NS</td>
</tr>
<tr>
<td>Fasting glucose (mmol/l)</td>
<td>4.9±0.6</td>
<td>4.9±0.7</td>
<td>4.9±0.6</td>
<td>NS</td>
</tr>
<tr>
<td>2-h glucose (mmol/l)</td>
<td>5.9±1.9</td>
<td>5.9±2.0</td>
<td>5.4±1.4</td>
<td>NS</td>
</tr>
<tr>
<td>AUC glucose</td>
<td>19.1±4.7</td>
<td>19.0±4.8</td>
<td>18.1±3.5</td>
<td>NS</td>
</tr>
<tr>
<td>HOMA-β (%)</td>
<td>260.6±175.9</td>
<td>248.2±184.9</td>
<td>209.5±113.5</td>
<td>NS²</td>
</tr>
<tr>
<td>Total cholesterol (mmol/l)</td>
<td>5.0±2.8</td>
<td>5.0±1.1</td>
<td>5.0±1.0</td>
<td>NS</td>
</tr>
<tr>
<td>LDL cholesterol (mmol/l)</td>
<td>3.2±1.0</td>
<td>3.1±1.0</td>
<td>3.2±1.2</td>
<td>NS</td>
</tr>
<tr>
<td>HDL cholesterol (mmol/l)</td>
<td>1.5±0.5</td>
<td>1.4±0.5</td>
<td>1.5±0.5</td>
<td>NS</td>
</tr>
<tr>
<td>Triglycerides (mmol/l)</td>
<td>1.3±0.6</td>
<td>1.3±0.9</td>
<td>1.4±0.9</td>
<td>NS</td>
</tr>
<tr>
<td>Leptin (ng/ml)</td>
<td>35.5±25.2</td>
<td>36.6±24.2</td>
<td>26.1±17.6</td>
<td>0.026*</td>
</tr>
<tr>
<td>Ghrelin (pg/ml)</td>
<td>77.6±53.7</td>
<td>74.7±60.6</td>
<td>93.7±60.2</td>
<td>NS</td>
</tr>
</tbody>
</table>

BMI, body mass index; HOMA-IR, homeostatic model assessment of insulin resistance; QUICKI, quantitative insulin-sensitivity check index; AUC, area under the curve; HOMA-β, HOMA of β-cell function; LDL, low density lipoprotein; HDL, high density lipoprotein; NS, not significant. Statistical analysis by ANOVA or Kruskal–Wallis test as appropriate. *Significant differences by Tukey test CC vs TT, P=0.042. †Significant differences by Tukey test CC vs TT, P=0.034. §Not significant by measurements of ANOVA but significant differences between CC– and TT-women measured by unpaired t-test, P<0.05. ¶Not significant by Kruskal–Wallis test but significant differences between CC– and TT-women measured by Wilcoxon rank sum test, P<0.05. ‡Significant differences by Tukey test CC vs TC, P=0.033. §Significant differences by Tukey test CC vs TT, P=0.021.
of the three genotype groups was performed. A 5% weight loss after 6 months was found in 15 out of 28 CC women (53.6%), 22 out of 51 TC (43.1%), and 7 out of 26 TT PCOS patients (26.9%).

Discussion

G-protein mutations may cause either loss or gain of function by inactivating or activating signal transduction, thus leading to the clinical phenotype of either hormone deficiency or excess. We were interested in the question whether a variation in the gene encoding for the Gas subunit influences susceptibility to PCOS, a disease characterized by androgen excess.

![Figure 1](image1.png)  
**Figure 1** Changes in free androgen index (FAI) during metformin treatment in PCOS patients. The FAI was measured in 105 PCOS women before (0) and after 1 and 6 months of metformin and grouped according to GNAS1 genotype (CC, TC, TT). The decrease was significant in all PCOS subgroups by Wilcoxon sign rank test (CC, \( P = 0.0271 \); TC, \( P < 0.0001 \); TT, \( P = 0.0005 \)). Data are shown by box and whiskers graph. The box extends from the 25th to the 75th percentile, with a line at the median indicating the 50th percentile. The whiskers represent the ranges extending from the lowest to the highest value.

![Figure 2](image2.png)  
**Figure 2** Menstrual cyclicity during metformin treatment in PCOS women. Menstrual cyclicity was recorded in 105 PCOS women before (0) and after 6 months of metformin treatment and grouped according to GNAS1 T393C genotype (CC, TC, TT). The percentage of women with amenorrhea (A) is shown by black, the percentage with those oligomenorrhea (O) by gray and those with normal menstrual cyclicity (N) by white bars.

![Figure 3](image3.png)  
**Figure 3** Changes in insulin resistance during metformin treatment in PCOS patients. Homeostatic model of insulin resistance (HOMA-IR) was measured in 105 PCOS women before (0) and after 1 and 6 months of metformin and grouped according to GNAS1 genotype (CC, TC, TT). The decrease was significant by Wilcoxon sign rank test in all PCOS genotype groups (CC, \( P = 0.006 \); TC, \( P < 0.0001 \); TT, \( P = 0.0001 \)). Data are shown by box and whiskers graph. The box extends from the 25th to the 75th percentile, with a line at the median indicating the 50th percentile. The whiskers represent the ranges extending from the lowest to the highest value.

![Figure 4](image4.png)  
**Figure 4** Weight change during metformin treatment in PCOS patients. Body weight was measured in 105 PCOS women before (0) and after 1 and 6 months of metformin treatment and grouped according to GNAS1 genotype (CC, TC, TT). The decrease was found to be significant by paired \( t \)-test in all groups after 6 months of treatment (CC, \( P < 0.0001 \); TC, \( P < 0.0001 \); TT, \( P = 0.0475 \)). Data are shown by box and whiskers graph. The box extends from the 25th to the 75th percentile, with a line at the median indicating the 50th percentile. The whiskers represent the ranges extending from the lowest to the highest value.
In our German PCOS study cohort, genotype distribution of the T393C polymorphism of the GNAS1 was in accordance with previous studies of other disease entities (28, 36, 37). In addition, there was no association of the GNAS1 polymorphism with any endocrine clinical and biochemical variable in PCOS women, thus suggesting that the T393C polymorphism does not contribute to the etiology of PCOS. However, in contrast to healthy control women, the PCOS study group of C-allele carriers showed significantly higher mean body weight, BMI values, indices of insulin resistance, and leptin levels. The gene encoding the Gas subunit (GNAS1) is located at chromosome 20q13.2–13.3. Data showing that this locus is linked to obesity and total energy intake (18) seem to be in accordance with our observation of altered BMI values in PCOS patients. Subgroup analyses of lean, overweight, and obese women showed significant differences in the genotype distribution according to BMI values, possibly in concert with environmental or behavioral factors. Such a gene–environment interaction has been shown for a polymorphism in the gene encoding the β2-adrenergocceptor, which exerts no effect on BMI in individuals with regular physical activity (38). While the percentage of women who regularly exercised did not differ between the genotype groups, we did not record the frequency and extend of physical activity and, thus, cannot exactly address this question.

The specific role of the T393C polymorphism in obesity is unclear. The few studies on transgenic animals or cell lines focus on the role of G proteins in adipogenesis. Su et al. (39) demonstrated that increasing Gi α 2 activity promotes adipogenic conversion, thus implicating G-proteins as possible regulators of adipogenesis. In humans, no studies on the molecular mechanisms of GNAS1 in obesity are available. The T393C polymorphism is silent, not changing the amino acid of the affected codon in exon 5 of the GNAS1 gene. However, we have previously shown that the GNAS1 polymorphism is associated with altered Gas mRNA expression in different tissues (35). We found that the T>C substitution at position 393 changes the mRNA folding structures (37). Therefore, genotype-dependent differences in mRNA decay due to altered secondary structure could finally cause differences in Gas mRNA expression. Nevertheless, a genetic alteration in the regulatory sequences of GNAS1, e.g. in the promoter, which could be in linkage disequilibrium with the T393C polymorphism and, which would affect transcription and expression of Gas cannot be excluded.

The entire PCOS cohort and the Metformin-treated German PCOS patients, no significant association between the GNAS1 T393C polymorphism and treatment outcome with regard to endocrine variables was found. In addition, while there was a trend towards a greater weight reduction in C-allele carriers, multivariate analysis showed that weight loss was predicted by the initial body weight and not by GNAS1 genotype. In conclusion, the presence of the GNAS1 T393C polymorphism is not associated with PCOS, but seems to influence the degree of obesity and insulin resistance in affected women. Further studies are required to clarify the molecular mechanism that underlie these findings.

References

30 ESHRE/ASRM. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. *Fertility and Sterility* 2004 **81** 19–25.
34 Matsuda M & DeFronzo RA. Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. *Diabetes Care* 1999 **22** 1462–1470.
40 Wijeyeratne CN, Balen AH, Barth JH & Belchetz PE. Clinical manifestations and insulin resistance (IR) in polycystic ovary syndrome (PCOS) among South Asians and Caucasians: is there a difference? *Clinical Endocrinology* 2002 **57** 343–350.

Received 7 May 2006
Accepted 29 August 2006